ForSight Robotics, a pioneer in ophthalmic robotic surgery, announced it completed a $125 million Series B round led by Eclipse. Along with Eclipse, the funding round included significant participation from an undisclosed strategic investor, Dr. Fred Moll, the Adani Group, Reiya Ventures, and other existing investors. This round brings ForSight Robotics’ total funding to $195 million.
Hundreds of millions of people worldwide suffer from preventable vision impairment and avoidable blindness, which is punctuated by a limited and declining ophthalmologist workforce. The demand for ophthalmologist services is expected to continue surging, while the availability of these services declines.
ORYOM Platform: The ORYOM Platform is engineered for precise and consistent ophthalmic procedures, starting with cataract surgery. With AI-based algorithms, advanced computer vision, and micromechanics, the robotic surgery platform aims to deliver unprecedented dexterity and maneuverability while providing surgeons with an improved ergonomic experience. The ORYOM Platform can reach any point within the human eye, enabling surgeons to navigate complex angles and ensuring access to both anterior and posterior segments, setting the stage for glaucoma and retinal surgical treatment.
What the funding will be used for: The funding accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, increase patient access to high-quality treatment, and decrease the physical burden on surgeons, as the company prepares to launch first-in-human clinical trials this year.
Momentum: The funding follows a period of rapid growth and key company achievements. In the past year, ForSight Robotics – which was founded by Prof. Moshe Shoham, Dr. Daniel Glozman, and Dr. Joseph Nathan – has expanded its executive team, received a ISO 13485:2016 certification, a critical regulatory milestone demonstrating the company’s commitment to safety and quality, and doubled in size, surpassing 110 employees as it grows to meet increasing demand. To date, over two dozen ophthalmic surgeons have completed hundreds of procedures on animal eye models with the ORYOM Platform. ForSight Robotics is set to begin robotic cataract surgery clinical trials in the coming year.
Advisory board: As the company scales, the founding team has convened a strategic advisory board of the preeminent leaders in surgical robotics, including Dr. Fred Moll, the founder of Intuitive Surgical and the da Vinci surgical system, who is widely regarded as the father of surgical robotics and Rony Abovitz, the founder of MAKO Surgical Corp. Dr. Fred Moll recently joined the company’s board of directors. Additionally, ForSight Robotics benefits from the expertise of a world-class clinical advisory board that includes Dr. David Chang, Dr. Vance Thompson, Prof. Boris Malyugin, Dr. Sam Garg, and Dr. Modi Naftali.
KEY QUOTES:
“We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical. With a comparable market size and an urgent global need, our opportunity ahead is immense. Through our latest funding round, we will bring the same level of transformative impact to eye surgery, with technology designed specifically for its unique precision and complexity.”
Dr. Joseph Nathan, ForSight Robotics’ co-founder, president, and Chief Medical Officer
“ForSight Robotics is at the forefront of a transformation in surgical robotics, and the potential impact of its technology on global eye care is extraordinary. The company is tapping into a massive, underserved market with a breakthrough approach to ophthalmic surgery, positioning itself to set a new standard in eye care and drive innovation on a global scale.”
Seth Winterroth, partner at Eclipse
